Abstract 4228
Background
Lipiodol transcatheter arterial chemoembolization (TACE) , known as c-TACE , is widely used to treat hepatocellular carcinoma (HCC). Recently, a drug-eluting bead (DEB) has been developed to sustain continual drug delivery to the tumor. We evaluate the efficacy and safety of TACE with doxorubicin-loaded drug eluting beads (D-TACE) in this study.
Methods
This retrospective study included 228 unresectable HCC patients who received cTACE (n = 153) or D-TACE(n = 75) in Zhongshan hospital, Fudan University from September 2018 to February 2019. Tumor response were evaluated by MRI according mRECIST one month after treatment, and adverse events were recorded as well.
Results
The disease control rate(DCR) of D-TACE was 78.6% versus 49.3% of c-TACE(p = 0.03),which demonstrated D-TACE had the better tumor reponse. There were no treatment related major complications in all patients, and no statistically significant difference in postembolization syndrome , liver toxicity and hematological toxicity between two groups(p > 0.05). Subgroup analyses indicated that patients with tumor size less than 7cm and tumor numbers less than 3 favored D-TACE , while there was no significant difference in efficacy in the patients with tumor size greater than 10cm (P > 0.05).
Conclusions
In unresectable HCC, transcatheter treatment with DEB loaded with doxorubicin offers a better objective tumor response than conventional TACE, especially in patients with tumor size less than 7cm and tumor numbers less than 3.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract